| Symbol |
YME1L1 |
| Full Name |
YME1 Like 1 ATPase (mitochondrial inner membrane protease) |
| Aliases |
YME1L, ATP-dependent protease YME1L |
| Chromosome |
10p11.23 |
| NCBI Gene |
10762 |
| Ensembl |
ENSG00000135547 |
| OMIM |
607472 |
| UniProt |
Q9Y4K0 |
| Protein Size |
757 amino acids (~84 kDa) |
| Expression |
Ubiquitous (high in brain, heart, muscle, liver) |
YME1L1 (YME1 Like 1 ATPase) is a critical mitochondrial inner membrane protease that belongs to the AAA (ATPases Associated with various cellular Activities) family of proteins. Located in the mitochondrial inner membrane, YME1L1 functions as an ATP-dependent metalloprotease that degrades misfolded or damaged proteins from the intermembrane space and inner membrane 1. This protease is essential for maintaining mitochondrial proteostasis, regulating mitochondrial dynamics (fusion and fission), and ensuring cellular survival under proteotoxic stress.
YME1L1 is part of the i-AAA protease complex (intermembrane space-facing AAA protease), which works in concert with the m-AAA protease (matrix-facing) to maintain mitochondrial protein quality control. The protein is ubiquitously expressed with high levels in tissues with high mitochondrial content, including brain, heart, and skeletal muscle 2.
Dysfunction of YME1L1 leads to severe neurological phenotypes. Mutations in YME1L1 cause Hereditary Spastic Paraplegia 77 (SPG77), a neurodegenerative disorder characterized by progressive lower limb spasticity, optic atrophy, and in some cases, intellectual disability 8. Additionally, YME1L1 deficiency is implicated in Parkinson's disease and other age-related neurodegenerative conditions 9.
¶ Structure and Function
¶ Protein Domain Architecture
YME1L1 is a ~757 amino acid protein with the following domain organization:
- N-terminal Mitochondrial Targeting Sequence (MTS): A cleavable presequence that directs the protein to the mitochondrial inner membrane
- Transmembrane Helix: Anchors the protein in the inner membrane
- AAA Module: Contains the ATPase activity
- Walker A motif (P-loop): Binds ATP
- Walker B motif: Coordinates metal ions and hydrolyzes ATP
- AAA+ domain: Provides mechanical force for protein unfolding
- Protease Domain: The catalytic domain with metalloprotease activity (HExxH motif)
YME1L1 functions as an ATP-dependent protease:
- Substrate Recognition: YME1L1 identifies misfolded or damaged proteins in the intermembrane space
- ATP Binding and Hydrolysis: ATP binding causes conformational changes; hydrolysis provides energy for protein unfolding
- Mechanical Unfolding: The AAA+ domain pulls on the substrate protein, unfolding it
- Proteolytic Degradation: The unfolded protein is translocated to the protease domain and degraded
This mechanism allows YME1L1 to handle proteins that cannot be degraded by the proteasome due to misfolding or aggregation.
YME1L1 functions as part of the i-AAA protease complex:
| Component |
Location |
Function |
| YME1L1 |
Inner membrane (IMS-facing) |
Primary proteolytic activity |
| YME1L (yeast ortholog) |
Inner membrane |
Conserved protease function |
| AFG3L2 |
Inner membrane (matrix-facing) |
m-AAA protease complex |
| SPG7 (PARAPLEGIN) |
Inner membrane |
m-AAA protease complex |
The i-AAA and m-AAA complexes have overlapping substrate specificities and cooperate to maintain mitochondrial proteostasis.
YME1L1 is essential for maintaining mitochondrial proteostasis:
Degradation of Misfolded Proteins:
- Removes proteins that fail to fold correctly
- Clears proteins with oxidative damage
- Degrades incompletely synthesized polypeptides
- Prevents accumulation of toxic protein aggregates 2
Substrate Processing:
- OPA1: Regulates processing of OPA1 (optic atrophy 1), a dynamin-like GTPase critical for mitochondrial fusion 7
- CLPP: Degrades misfolded proteins in the intermembrane space
- Oxidative damage victims: Clears proteins damaged by reactive oxygen species (ROS)
YME1L1 plays a critical role in regulating mitochondrial morphology:
Fusion Regulation:
- Processes OPA1 to generate long and short isoforms
- Long OPA1 mediates inner membrane fusion
- Short OPA1 promotes fission
- Maintains balance between fusion and fission 6
Network Maintenance:
- Loss of YME1L1 leads to mitochondrial fragmentation
- Enhanced fission due to altered OPA1 processing
- Disrupted mitochondrial networking in neurons 4
YME1L1 contributes to the mtUPR:
- Accumulation of misfolded proteins triggers mtUPR signaling
- YME1L1 activity helps resolve proteotoxic stress
- Coordinates with other mitochondrial quality control systems 11
YME1L1 is required for:
- Apoptotic resistance: Cells lacking YME1L1 are more susceptible to apoptosis
- Cristae morphogenesis: Maintains proper inner membrane structure
- Cell proliferation: Essential for cell cycle progression
- Metabolic function: Supports oxidative phosphorylation and cellular energetics 3
YME1L1 exhibits ubiquitous expression:
- Brain: High expression in cortex, hippocampus, basal ganglia, and cerebellum
- Heart: Very high expression in cardiac muscle
- Skeletal muscle: High expression in myofibers
- Liver: Moderate expression in hepatocytes
- Kidney: Moderate expression
- All tissues: Any cell with mitochondria expresses YME1L1
In neurons, YME1L1 is particularly important due to:
- High metabolic demands
- Post-mitotic nature (cannot dilute damaged proteins through cell division)
- Long lifespan requiring decades of function
SPG77 (OMIM 617003) is an autosomal recessive disorder caused by YME1L1 mutations:
Clinical Features:
- Progressive spasticity of lower limbs (pure HSP)
- Variable optic atrophy (sometimes severe)
- Thin corpus callosum
- Intellectual disability (in some cases)
- Peripheral neuropathy
- Onset in infancy or early childhood 8
Genetics:
- Biallelic loss-of-function mutations
- Missense, nonsense, and frameshift variants identified
- Variable phenotype even within families
Pathophysiology:
- Loss of YME1L1 protease activity
- Accumulation of misfolded mitochondrial proteins
- Mitochondrial fragmentation and dysfunction
- Neuronal vulnerability, particularly in corticospinal tracts and optic nerve
YME1L1 mutations frequently cause optic atrophy:
- Progressive vision loss beginning in childhood
- Temporal pallor of optic nerve
- Variable severity (mild to severe blindness)
- Often in association with spastic paraplegia
The optic nerve is particularly vulnerable due to:
- High mitochondrial content in retinal ganglion cells
- Long axonal projections requiring efficient transport
- Energy demands for action potential propagation
Emerging evidence links YME1L1 to Parkinson's disease:
Mitochondrial Dysfunction: PD is characterized by mitochondrial defects; YME1L1 deficiency exacerbates these 9.
α-Synuclein Processing: YME1L1 may regulate proteins involved in α-synuclein aggregation.
Dopaminergic Neuron Vulnerability: YME1L1 loss particularly affects dopaminergic neurons in the substantia nigra.
Genetic Associations: YME1L1 variants may modify PD risk.
While less directly studied:
- Mitochondrial dysfunction is a hallmark of AD
- YME1L1 deficiency may contribute to amyloid-induced mitochondrial damage
- Could exacerbate tau pathology through mitochondrial stress
- Huntington's disease: Mitochondrial dysfunction involves YME1L1-related pathways
- ALS: Mitochondrial quality control is impaired
- Peripheral neuropathies: YME1L1 mutations cause axonal degeneration
YME1L1 plays a central role in cellular energy metabolism:
Oxidative Phosphorylation (OXPHOS):
- Maintains electron transport chain complex integrity
- Prevents accumulation of misfolded OXPHOS subunits
- Supports proper complex assembly and function
ATP Production:
- Loss of YME1L1 reduces cellular ATP levels
- Particularly affects high-energy-demand cells like neurons
- Contributes to synaptic dysfunction and neuronal loss
Metabolic Flexibility:
- YME1L1 helps cells adapt to different metabolic demands
- Supports shift between glycolysis and oxidative phosphorylation
- Important during cellular stress or nutrient changes
¶ Calcium Handling
YME1L1 influences mitochondrial calcium dynamics:
- Mitochondrial calcium uptake requires functional mitochondria
- Calcium dysregulation contributes to neuronal death
- YME1L1 deficiency disrupts calcium buffering capacity
- Links metabolic dysfunction to excitotoxicity
YME1L1 affects mitochondrial lipid composition:
- Cardiolipin metabolism is altered in YME1L1 deficiency
- Affects mitochondrial inner membrane structure
- Influences electron transport chain function
- Lipid droplet accumulation observed in some models
The yeast ortholog Yme1 has been extensively studied:
- Deletion of YME1 causes respiratory deficiency
- Accumulation of misfolded proteins in mitochondria
- Enhanced chronological aging phenotypes
- Key substrate identification from yeast studies
Conditional Knockout Studies:
- Brain-specific Yme1l1 deletion causes neurodegeneration
- Cortical neuron loss observed
- Retinal degeneration mimics optic atrophy
- Behavioral deficits in motor coordination
Transgenic Models:
- Expressing mutant YME1L1 recapitulates HSP phenotype
- Mitochondrial fragmentation in neurons
- Progressive disease course modeling human SPG77
Patient-derived cells provide insights:
- Fibroblasts from SPG77 patients show mitochondrial defects
- Reduced OXPHOS capacity
- Increased sensitivity to stress
- Rescue with wild-type YME1L1 expression
¶ Diagnostic and Clinical Considerations
YME1L1 mutation testing:
- Panel-based testing for hereditary spastic paraplegia
- Whole exome sequencing for undiagnosed cases
- Variant interpretation following ACMG guidelines
- Family member testing for variant segregation
Potential biomarkers under investigation:
- Mitochondrial function in patient-derived cells
- OXPHOS complex assembly
- OPA1 processing patterns
- Neuroimaging for disease progression
YME1L1-related disorders overlap with:
- Other hereditary spastic paraplegias (SPG7, SPG15)
- Leber's hereditary optic neuropathy
- Mitochondrial myopathies
- Variable phenotypic presentations
¶ Research Directions and Future Perspectives
Single-Cell Approaches:
- Understanding cell-type-specific vulnerability
- Transcriptomic profiling of affected neurons
- Spatial transcriptomics in brain tissue
Proteomics:
- Global substrate identification
- Interactome mapping
- Post-translational modification analysis
Structural Studies:
- Cryo-EM structures of YME1L1 complexes
- Mechanism of substrate recognition
- Protease activation mechanisms
Gene Therapy Approaches:
- AAV-mediated YME1L1 delivery
- Gene editing with CRISPR/Cas9
- Splice-correcting oligonucleotides
Small Molecule Strategies:
- Protease activity enhancers
- Mitochondrial protective agents
- Protein aggregation inhibitors
Combination Therapies:
- Targeting multiple pathways simultaneously
- Symptomatic and disease-modifying approaches
- Personalized treatment based on mutation type
YME1L1 plays essential roles during neural development:
Mitochondrial Biogenesis:
- Critical for mitochondrial network formation in developing neurons
- Supports neuronal differentiation and maturation
- Enables proper dendritic arborization
Synaptogenesis:
- Mitochondrial function essential for synapse formation
- YME1L1 deficiency impairs synaptic connectivity
- Affects both excitatory and inhibitory synapses
Neuronal vulnerability varies across development:
- Embryonic development: Mitochondrial requirements for rapid proliferation
- Postnatal period: Synapse formation and refinement
- Adolescence: Maturation of mitochondrial networks
- Adult: Maintenance and quality control
Symptomatic Management:
- Spasticity management with baclofen, tizanidine
- Physical therapy for mobility preservation
- Occupational therapy for daily living
- Regular ophthalmologic evaluation
Disease Monitoring:
- Neurological assessments every 6-12 months
- Visual acuity monitoring
- Imaging for disease progression
Clinical Trials:
- Mitochondrial protective agents under investigation
- Gene therapy trials in early stages
- Small molecule screening for protease activators
Supportive Care:
- Multidisciplinary approach
- Genetic counseling for families
- Psychosocial support
-
Proteostasis Failure
- Accumulation of misfolded mitochondrial proteins
- Formation of toxic protein aggregates
- Disruption of mitochondrial protein complexes
-
Mitochondrial Dynamics Dysregulation
- Excessive fission due to altered OPA1 processing
- Fragmented mitochondrial networks
- Impaired mitochondrial transport in axons
-
Energy Failure
- Reduced oxidative phosphorylation capacity
- Decreased ATP production
- Impaired calcium handling
-
Neuronal Vulnerability
- Specific loss of corticospinal tract neurons
- Retinal ganglion cell degeneration
- Synaptic dysfunction and loss
- Oxidative stress: Increased ROS production
- Neuroinflammation: Activated glial responses
- Apoptotic cell death: Caspase-dependent neuronal loss
- Axonal degeneration: Distal-first pattern typical of HSP
YME1L1 interacts with several key proteins:
| Protein |
Interaction Type |
Function |
| OPA1 |
Substrate/regulator |
Mitochondrial fusion GTPase |
| CLPP |
Protease complex |
Intermembrane space protease |
| AFG3L2 |
Protease complex |
m-AAA protease component |
| SPG7 |
Protease complex |
m-AAA protease component |
| PMP22 |
Substrate |
Peripheral myelin protein |
| Tmem135 |
Regulatory |
Mitochondrial dynamics |
- Yme1l1 conditional knockout: Brain-specific deletion causes neurodegeneration
- Knock-in models: Expressing disease-causing variants
- Morpholino knockdown: Recapitulates optic atrophy phenotype
- Yme1 deletion: Studying protease function and substrates
-
Gene Therapy: Delivering functional YME1L1
- AAV vectors under development
- Challenges: large gene size, mitochondrial targeting
-
Small Molecule Stabilizers: Enhancing remaining YME1L1 activity
-
Mitochondrial Protectants: Reducing oxidative stress
- CoQ10 and analogs
- Mitochondrial-targeted antioxidants
-
Symptomatic Treatments: Managing spasticity and optic atrophy
- Protein replacement therapy: Delivering functional protease
- Substrate-specific therapies: Targeting downstream pathways
- Combination approaches: Multiple mechanisms
¶ Fusion and Fission Balance
YME1L1 plays a critical role in regulating mitochondrial morphology:
OPA1 Processing:
- YME1L1 processes OPA1 (optic atrophy 1)
- Generates long and short OPA1 isoforms
- Long OPA1 mediates inner membrane fusion
- Short OPA1 promotes fission
Balance Maintenance:
- Loss of YME1L1 disrupts OPA1 processing
- Leads to excessive mitochondrial fission
- Results in fragmented mitochondrial networks
- Impairs mitochondrial function and distribution
The fusion-fission balance is critical:
- Neuronal energy demands: Requires proper mitochondrial distribution
- Axonal transport: Fragmented mitochondria cannot be transported efficiently
- Synaptic function: Mitochondria must reach synaptic terminals
- Calcium handling: Disrupted networks impair calcium homeostasis
YME1L1 expression is regulated at the transcriptional level:
Promoter Elements:
- GC-rich promoter region
- Response to cellular stress
- Regulation by transcription factors
Environmental Factors:
- Mitochondrial stress response
- Metabolic signals
- Oxidative stress
YME1L1 is regulated post-transcriptionally:
- mRNA stability: Affected by cellular conditions
- Alternative splicing: Generates tissue-specific isoforms
- MicroRNA regulation: Several miRNAs target YME1L1
Diagnosing YME1L1-related disorders:
Genetic Testing:
- Whole exome sequencing
- Targeted gene panels
- Family segregation analysis
Clinical Evaluation:
- Neurological examination
- Ophthalmological assessment
- Neuroimaging (MRI)
Current management approaches:
- Symptomatic treatment: Managing spasticity
- Ophthalmological care: Vision support
- Physical therapy: Maintaining mobility
- Genetic counseling: Family planning
Key approaches to studying YME1L1:
- Biochemistry: Protease activity assays, substrate identification
- Cell biology: Mitochondrial morphology, live cell imaging
- Genetics: CRISPR models, patient-derived cells
- Proteomics: Identifying YME1L1 substrates and interactors
YME1L1 works with other quality control mechanisms:
Proteasome System:
- Degrades cytosolic proteins
- Cooperates with mitochondrial quality control
- Prevents accumulation of damaged proteins
Mitochondrial Proteostasis Network:
- Chaperone systems (mtHsp70)
- Other proteases (AFG3L2, CLPP)
- Import machinery
The mitochondrial unfolded protein response:
- Activated by YME1L1 substrates
- Coordinates nuclear gene expression
- Increases chaperone expression
- Promotes mitochondrial stress resistance
YME1L1 is evolutionarily conserved:
- Present in all eukaryotes
- Yeast ortholog (YME1)
- Essential in many organisms
- Domain structure conserved
Studying YME1L1 in model systems:
- Yeast: Genetic screens, substrate identification
- C. elegans: Development studies, longevity
- Zebrafish: Development and vision
- Mouse: Disease modeling
Key areas for future research:
- Substrate identification: Comprehensive catalog of YME1L1 substrates
- Structural studies: Understanding protease mechanism
- Therapeutic development: Small molecule activators
- Biomarkers: Disease progression markers
New approaches to study YME1L1:
- Single-cell proteomics: Substrate mapping
- Cryo-EM: Structural visualization
- CRISPR screening: Synthetic lethality partners
- Organoids: Disease modeling
YME1L1 and related proteins could serve as biomarkers:
- YME1L1 levels: Reduced in patient cells
- OPA1 processing: Altered isoform ratios
- Mitochondrial stress markers: Elevated in plasma
- Neurofilament light chain: Axonal damage marker
Biomarkers for treatment response include mitochondrial function assays, protease activity measurements, and imaging markers for optic atrophy.
¶ YME1L1 and the Mitochondrial Proteostasis Network
YME1L1 works in concert with multiple mitochondrial quality control mechanisms:
Mitochondrial Import Machinery:
- The TOM/TIM complexes import proteins into mitochondria
- YME1L1 degrades proteins that fail to properly fold after import
- Prevents accumulation of non-functional polypeptides
Inner Membrane Proteases:
- AFG3L2: Matrix-facing m-AAA protease
- SPG7 (Paraplegin): m-AAA protease component
- These proteases have overlapping substrate specificities
- Cooperation ensures comprehensive quality control
Chaperone Systems:
- mtHsp70 (PBP1/Phenotype): Matrix chaperone
- Tiny chaperones: IMS chaperones
- YME1L1 coordinates with chaperones to manage proteotoxic stress
The mitochondrial unfolded protein response (mtUPR) is activated by YME1L1 substrates:
- Stress Sensing: Accumulation of YME1L1 substrates in IMS
- Signal Transduction: ATFS-1 (DVE in mammals) senses stress
- Nuclear Signaling: ATFS-1 translocates to nucleus
- Gene Activation: Increases expression of mitochondrial chaperones
- Proteostasis Restoration: Enhanced chaperone capacity resolves stress
This pathway is critical for maintaining mitochondrial function under proteotoxic stress conditions.
Clinical diagnosis of YME1L1-related disorders involves:
Genetic Testing:
- Whole exome sequencing is primary diagnostic tool
- YME1L1 included in mitochondrial disease panels
- Hereditary spastic paraplegia gene panels
- Family segregation analysis for recessive inheritance
Biochemical Markers:
- Plasma/CSF lactate elevation
- Decreased mitochondrial respiratory function
- Abnormal OPA1 processing on Western blot
- Elevated FGF21 and GDF15 (markers of mitochondrial stress)
Imaging Findings:
- MRI may show thin corpus callosum
- Optic nerve atrophy on MR or OCT
- White matter changes in some cases
Current clinical management includes:
Neurological Care:
- Spasticity management (baclofen, tizanidine)
- Physical therapy for mobility
- Occupational therapy for daily activities
- Regular neurological assessments
Ophthalmological Care:
- Regular visual acuity monitoring
- Low vision aids when needed
- Genetic counseling for families
Systemic Support:
- Multidisciplinary care team
- Regular monitoring for complications
- Genetic counseling
Gene therapy represents a promising approach:
AAV-Mediated Delivery:
- AAV vectors can deliver YME1L1 cDNA
- Tissue-specific promoters for neuronal targeting
- Challenges: large gene size (~2.3 kb cDNA)
- Ongoing preclinical studies
CRISPR-Based Therapies:
- Base editing for specific mutations
- Gene activation to increase expression
- In vivo delivery challenges
Protease Activators:
- Compounds that enhance YME1L1 activity
- High-throughput screening for activators
- Allosteric modulators
Mitochondrial Protectants:
- CoQ10 and analogs (ubiquinone)
- Mitochondrial-targeted antioxidants (MitoQ)
- Latrepirdine (dimebolin)
Metabolic Support:
- L-carnitine supplementation
- Alpha-lipoic acid
- B-vitamin complex
Research on YME1L1 uses multiple model systems:
Yeast (S. cerevisiae):
- YME1 deletion mutants
- Substrate identification
- Mechanism studies
- Fast genetic screening
C. elegans:
- Developmental studies
- Neuronal function
- Longevity research
Zebrafish:
- Morpholino knockdown
- Visual system studies
- Development
Mouse Models:
- Conditional knockout systems
- Disease modeling
- Therapeutic testing
¶ Reagents and Assays
Key research tools:
Biochemical Assays:
- ATPase activity measurements
- Protease substrate degradation
- Protein interaction assays
Cellular Assays:
- Mitochondrial morphology (MitoTracker)
- Oxygen consumption rate ( Seahorse)
- Cell viability under stress
Genetic Tools:
- CRISPR/Cas9 knockout
- siRNA/shRNA knockdown
- Flag/HA-tagged constructs
- Substrate specificity: What determines which proteins YME1L1 degrades?
- Regulation: How is YME1L1 activity modulated?
- Therapeutic targeting: Can we develop targeted therapies?
- Biomarkers: What are the best disease biomarkers?
- Patient stratification: What predicts disease severity?
- Single-cell approaches: Understanding cell-type specificity
- Structural biology: Cryo-EM studies of YME1L1
- Organoid models: Patient-derived disease modeling
- Gene therapy: Viral delivery approaches